OTCMKTS:PROT - Stromacel Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.0250 +0.01 (+66.67 %) (As of 10/23/2018 04:00 PM ET)Previous Close$0.0195Today's Range$0.0250 - $0.025052-Week Range$0.01 - $0.07Volume1,000 shsAverage Volume9,081 shsMarket Capitalization$79,110.00P/E RatioN/ADividend YieldN/ABeta0.63 ProfileDiscussionChartFinancialsHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Proteonomix, Inc., a biotechnology company, focuses on developing therapeutics based upon the use of human cells and their derivatives. The company's products include Proteoderm, an anti-aging skin cream based on a proprietary and patented matrix of proteins that reduce wrinkles; UMK-121, a treatment for liver disease using a combination of two or three approved drugs to mobilize particular bone marrow stem cells; and StromaCel, a treatment for cardiac patients within two weeks of a myocardial infarction using stem cells derived from donor bone marrow and administered through IV solution to repair heart tissue. Its products also comprise NC-138, a proprietary matrix of proteins, which act on the skin to enhance activities that reduce wrinkles. The company was formerly known as National Stem Cell Holding, Inc. and changed its name to Proteonomix, Inc. in August 2008. Proteonomix, Inc. was incorporated in 1995 and is based in Hawthorne, New Jersey. Receive PROT News and Ratings via Email Sign-up to receive the latest news and ratings for PROT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:PROT Previous Symbol CUSIPN/A Webstromacel.com Phone+1-973-5446116 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on Equity3,244.33% Return on Assets90.15% Miscellaneous EmployeesN/A Outstanding Shares7,910,000Market Cap$79,110.00 OptionableN/A Stromacel (OTCMKTS:PROT) Frequently Asked Questions What is Stromacel's stock symbol? Stromacel trades on the OTCMKTS under the ticker symbol "PROT." Who are some of Stromacel's key competitors? Some companies that are related to Stromacel include Arno Therapeutics (ARNI), Diagnocure (DGCRF), Medican Enterprises (MDCN), Altimmune (ALT), Axim Biotechnologies (AXIM), Can-Fite Biopharma (CANF), Circassia Pharmaceuticals (CIR), Cronos Group (CRON), Devonian Health Group (GSD), Exicure (XCUR), Galena Biopharma (SLS), Immunoprecise Antibodies (IPATF), IMV (IMV), Kodiak Sciences (KOD) and Naturally Splendid Enterprises (NSP). Who are Stromacel's key executives? Stromacel's management team includes the folowing people: Mr. Michael Cohen, Founder, Chairman, CEO, Pres & COO (Age 51)Mr. Steven Byle J.D., Chief Technology Officer and Director (Age 50)Mr. Jason B. Isaacs, Sec. (Age 46)Ms. Jaci Mandil, Chief Exec. Officer of Proteoderm How do I buy shares of Stromacel? Shares of PROT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Stromacel's stock price today? One share of PROT stock can currently be purchased for approximately $0.0250. How big of a company is Stromacel? Stromacel has a market capitalization of $79,110.00. What is Stromacel's official website? The official website for Stromacel is http://stromacel.com/. How can I contact Stromacel? Stromacel's mailing address is 187 Mill Ln, MOUNTAINSIDE, NJ 07092-2918, United States. The biotechnology company can be reached via phone at +1-973-5446116. MarketBeat Community Rating for Stromacel (OTCMKTS PROT)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 20 (Vote Outperform)Underperform Votes: 22 (Vote Underperform)Total Votes: 42MarketBeat's community ratings are surveys of what our community members think about Stromacel and other stocks. Vote "Outperform" if you believe PROT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PROT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 10/23/2018 by MarketBeat.com StaffFeatured Article: What are the Benefits of Index Funds?